Aspire-Lakewood (ASBP) vs Cellectar Biosciences (CLRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 43.0% versus a loss of 70.7%. Cellectar Biosciences is the larger company by market cap ($13.2 million vs $11.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | CLRB |
|---|---|---|
| Share price | $8.30 | $1.40 |
| Market cap | $11.64M | $13.23M |
| 1-day change | -3.82% | -7.28% |
| YTD return | +57.20% | -52.54% |
| 1-year return | -42.99% | -70.71% |
| 5-year return | — | -99.49% |
| EPS (TTM) | $-30.89 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.76 | $5.07 |
| 52-week low | $0.11 | $1.34 |
| Distance from 52-week high | -55.76% | -72.39% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +721.43% |
| Average volume | 36.92K | 63.86K |
| Shares outstanding | 1.40M | 9.45M |
| Employees | — | 11 |
| Sector | Consumer Cyclical | Healthcare |
| Industry | Auto Parts | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed CLRB by 27.7 percentage points over the past year.
- The two companies sit in different sectors: Aspire-Lakewood in Consumer Cyclical and Cellectar Biosciences in Healthcare.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Consumer Cyclical · Auto Parts
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
ASBP vs CLRB FAQ
Which is bigger, Aspire-Lakewood or Cellectar Biosciences?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.23M compared with $11.64M for Aspire-Lakewood (ASBP).
Which stock has performed better over the past year, ASBP or CLRB?
ASBP returned -42.99% over the past 12 months, compared with -70.71% for CLRB (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and Cellectar Biosciences in the same industry?
No. Aspire-Lakewood is in the Consumer Cyclical sector, while Cellectar Biosciences is in Healthcare.